Hearing on: Biologics and Biosimilars: Balancing Incentives for Innovation
Tuesday 07/14/2009 - 2:00 P.M.
2141 Rayburn House Office Building
Subcommittee on the Courts and Competition Policy
By Direction of the Chairman
Hearing Documentation
Hearing PDF (Serial No. 111-73)
Related News
No related news available
|
|
|
Witness List
Panel I
|
Hon. Anna G. Eshoo
U.S. House of Representatives
14th District, CA
|
Panel II
|
Bruce A. Leicher
Senior Vice President and General Counsel
Momenta Pharmaceuticals, Inc.
Cambridge, MA
|
Jeffrey P. Kushan
on behalf of the Biotechnology Industry Organization (BIO)
Woodrow Wilson School of Public and International Affairs
Princeton, NJ
|
Alex M. Brill
Research Fellow
American Enterprise Institute (AEI)
Washington, DC
|
Jack W. Lasersohn
General Partner
Verticle Group
on behalf of National Venture Capital Association (NVCA)
Arlington, VA
|
Larry McNeely
Healthcare Reform Advocate
U.S. Public Interest Research Groups (USPIRG)
Washington, DC
|
Teresa Stanek Rea
President
American Intellectual Property Law Association (AIPLA)
Washington, DC |
|
